close
Edit Metric
Company
Value
Source
Source URL
Notes
Cancel
 
close
Edit  |  History
Details
Company:
Value :
Source:
Source URL:
Notes:
 
Feedback
Get involved
FAQ

Add a New Bears Reason
Company: Schering-Plough (SGP)
Current price:
Headline: (100 character max)
Analysis:
Cancel
0%
agree
0 votes

edit Pipeline does not have a strong outlook

Created when SGP was $29.52 | Edit | History

The pipeline does not have a strong outlook, with fairly few drugs coming out in the near future. Drug failures are common during development, and Schering-Plough is in a difficult position in having so few potential candidates.

(100 character max) Cancel
0%
agree
0 votes

edit Recent challenges to Zetia would be a huge blow

Created when SGP was $29.52 | Edit | History

While many of Schering-Plough's patents do not expire for several years, the recent challenges to Zetia would be a huge blow to a company that relies on this drug for most of its revenue.

(100 character max) Cancel
0%
agree
0 votes

edit Organon was expensive acquisition for Schering-Plough

Created when SGP was $29.52 | Edit | History

Organon was a particularly expensive acquisition for Schering-Plough, costing about 3 times its total sales and 15 times its operating profits. If Organon does not pay off, Schering-Plough will have wasted a substantial amount of resources.

(100 character max) Cancel
The Shelf
Contributions
Help make Wikinvest better! Learn how to get involved. And create an account to build your reputation.
Did you know…?
Bookmarks
Worried about pump and dump?
We review changes
for stock spam
» read more
Want to make Wikinvest better?
We need your help,
contribute today
» learn how
Do you write software?
We are recruiting
the best engineers
» view jobs
Like Wikinvest?
Spread the word —
Tell your friends!
» spread the word
Wikinvest © 2006, 2007, 2008. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki